one
TREATMENT OF NEUROLOGICAL DISEASE
Last updated:
Abstract:
The invention is directed to 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol for the treatment of diseases mediated by protein misfolding, heat shock factor 1 pathways, or nuclear erythroid 2-related factor 2 pathways.
Status:
Application
Type:
Utility
Filling date:
18 Oct 2019
Issue date:
25 Aug 2022